Literature DB >> 11063140

Treatment of vasculitic IgA nephropathy.

L Harper1, M A Ferreira, A J Howie, C O Savage, N T Richards, J Michael, D Adu.   

Abstract

BACKGROUND: Patients with IgA nephropathy and histological vasculitic/crescentic lesions have a poor prognosis. We performed a retrospective study to assess whether treatment with steroids and immunosuppressants would preserve renal function by healing these lesions and thereby prevent progression to glomerular sclerosis and renal failure.
METHODS: Sixteen patients with IgA nephropathy and a vasculitic/crescentic glomerulonephritis diagnosed by renal histology were treated with a reducing course of prednisolone (initial dose 60 mg/day). Six patients also received cyclophosphamide (2 mg/kg/day) for three months followed by azathioprine (100 mg/day) in five patients. Ten patients received azathioprine (100 mg/day) in addition to prednisolone. The median duration of treatment was 12 months (range 5-30 months). At the end of treatment each patient had a second renal biopsy.
RESULTS: Following treatment there was a significant reduction in the proportion of glomeruli with acute vasculitic lesions from a median of 17.4% (range 4.8-57.5%) to 0 (range 0-15.8%) (p=0.001). There was an increase in the proportion of globally sclerosed glomeruli from a median of 13.4% (range 0-44.4%) to 21.5% (range 0-90%) after treatment but this did not significantly differ from baseline (p=0.24). The proportion of renal cortex with chronic tubular atrophy increased from 2.55% (0.4-57.7%) to 11.3% (0.3-61%) (p=0.09). The median duration of follow-up was 30 months (inter-quartile range 6-30 months). At both 12 and 24 months there was no significant increase in serum creatinine. Four patients, however, developed end-stage renal failure between 24 and 81 months.
CONCLUSION: In this retrospective study we show that treatment with steroids and immunosuppressants leads to healing of vasculitic lesions and may thus arrest progression of glomerular scarring.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11063140

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  7 in total

Review 1.  Pathology of IgA nephropathy.

Authors:  Ian S D Roberts
Journal:  Nat Rev Nephrol       Date:  2014-05-27       Impact factor: 28.314

2.  Sequential therapy with cyclophosphamide and mycophenolic acid in patients with progressive immunoglobulin A nephropathy: a long-term follow-up.

Authors:  F M Rasche; F Keller; W G Rasche; S Schiekofer; T Kahn; J Fahnert
Journal:  Clin Exp Immunol       Date:  2015-11-26       Impact factor: 4.330

Review 3.  [IgA nephropathy: frequent, but rarely diagnosed].

Authors:  J Floege; H-J Gröne
Journal:  Internist (Berl)       Date:  2003-09       Impact factor: 0.743

4.  In crescentic IgA nephropathy, fractional excretion of IgG in combination with nephron loss is the best predictor of progression and responsiveness to immunosuppression.

Authors:  Claudio Bazzi; Virginia Rizza; Sara Raimondi; Daniela Casellato; Pietro Napodano; Giuseppe D'Amico
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-30       Impact factor: 8.237

5.  Deoxyspergualin, an immunosuppressant, in patients suffering from nephropathies with crescent formation: an open-label trial to evaluate safety and efficacy.

Authors:  Hirokazu Imai; Osamu Hotta; Mitsuhiro Yoshimura; Tsuneo Konta; Yoshiharu Tsubakihara; Masanobu Miyazaki; Chie Tomida; Masaki Kobayashi; Satoshi Suzuki; Hideo Shiiki; Atsushi Yamauchi; Hitoshi Yokoyama; Masato Nose
Journal:  Clin Exp Nephrol       Date:  2006-03       Impact factor: 2.801

6.  Clinicopathological characteristics and prognosis of patients with IgA nephropathy and renal vasculitic lesions.

Authors:  Xueqing Tang; Qiong Wen; Qian Zhou; Wei Chen
Journal:  BMC Nephrol       Date:  2021-10-28       Impact factor: 2.388

7.  Co-existing proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis with immunoglobulin A nephropathy.

Authors:  Adem Kucuk; Yalcin Solak; Abduzhappar Gaipov; Sinan Bagcaci; Hasan Esen; Suleyman Turk; Recep Tunc
Journal:  Korean J Intern Med       Date:  2015-12-28       Impact factor: 2.884

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.